Petr Holy (Petr Holý)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 9

Top Venues

International journal of cancer

Journal of personalized medicine

British journal of pharmacology

International journal of molecular sciences

Biomedical Center, Faculty of Medicine in Pilsen, Charles University

Charles University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Biomedical Center, Faculty of Medicine in Pilsen, Charles University

Czechia

Researcher :: Department of Pharmacogenomics

National Institute of Public Health

Czechia

Researcher :: Toxicogenomics Unit

Education History

Charles University Oct 01 2011

Czechia

PHD

Publications

Petr Holy, Viktor Hlavac, Karolina Seborova, Simona Šůsová, Tereza Tesarova, Lukáš Rob, Martin Hruda, Jiří Bouda, Alena Bartáková, Marcela Mrhalová, Kateřina Kopečková, Mohammad Al Obeed Allah, Jiří Špaček, Iva Sedláková, Pavel Souček, Radka Václavíková
Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression. International journal of cancer (2024)
Petr Holy, Viktor Hlavac, Karolina Seborova, Simona Šůsová, Tereza Tesarova, Lukáš Rob, Martin Hruda, Jiří Bouda, Alena Bartáková, Marcela Mrhalová, Kateřina Kopečková, Mohammad Al Obeed Allah, Jiří Špaček, Iva Sedláková, Pavel Souček, Radka Václavíková
Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression. International journal of cancer 155 (1) (2024)
Petr Holy, Viktor Hlavac, Karolina Seborova, Simona Šůsová, Tereza Tesarova, Lukáš Rob, Martin Hruda, Jiří Bouda, Alena Bartáková, Marcela Mrhalová, Kateřina Kopečková, Mohammad Al Obeed Allah, Jiří Špaček, Iva Sedláková, Pavel Souček, Radka Václavíková
Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression. International journal of cancer 155 (1) (2024)
Viktor Hlavac, Petr Holy, Pavel Souček
The potential of exome sequencing of paired colorectal tumors and synchronous liver metastases to improve treatment. Pharmacogenomics (2023)
Petr Holy, Veronika Brynychová, Karolína Šeborová, Vojtěch Haničinec, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Pavel Souček
Integrative analysis of mRNA and miRNA expression profiles and somatic variants in oxysterol signaling in early-stage luminal breast cancer. Molecular oncology (2023)
Viktor Hlavac, Petr Holy, Radka Václavíková, Lukáš Rob, Martin Hruda, Marcela Mrhalová, Petr Černaj, Jiří Bouda, Pavel Souček
Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy. Life science alliance 5 (12) (2022)
Karolina Seborova, Alzbeta Kloudova-Spalenkova, Kamila Koucka, Petr Holy, Marie Ehrlichova, Changwei Wang, Iwao Ojima, Iveta Voleska, Petr Daniel, Kamila Balušíková, Michael Jelinek, Jan Kovar, Lukas Rob, Martin Hruda, Marcela Mrhalova, Pavel Souček, Radka Vaclavikova
The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes. International journal of molecular sciences 23 (1) (2021)
Viktor Hlavac, Petr Holy, Pavel Souček
Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450. Journal of personalized medicine 10 (3) (2020)
Alzbeta Kloudova-Spalenkova, Petr Holy, Pavel Souček
Oxysterols in cancer management: From therapy to biomarkers. British journal of pharmacology 178 (16) (2020)

Petr Holy.css-eqlu8i{font-size:small;padding-left:4px;} (Petr Holý)

Publication Activity (10 Years)

Top Topics

Top Venues

Petr Holy (Petr Holý)